HRP20070542T3 - Sulfonamide derivatives for the treatment of diseases - Google Patents

Sulfonamide derivatives for the treatment of diseases

Info

Publication number
HRP20070542T3
HRP20070542T3 HR20070542T HRP20070542T HRP20070542T3 HR P20070542 T3 HRP20070542 T3 HR P20070542T3 HR 20070542 T HR20070542 T HR 20070542T HR P20070542 T HRP20070542 T HR P20070542T HR P20070542 T3 HRP20070542 T3 HR P20070542T3
Authority
HR
Croatia
Prior art keywords
group
alkyl
optionally substituted
halogen
diseases
Prior art date
Application number
HR20070542T
Other languages
Croatian (hr)
Inventor
D. Brown Alan
E. Bunnage Mark
A. Glossop Paul
James Kim
A.L. Lane Charlotte
A. Lewthwaite Russell
B. Moses Ian
A. Price David
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34890770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20070542(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Priority claimed from PCT/IB2005/000086 external-priority patent/WO2005080313A2/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20070542T3 publication Critical patent/HRP20070542T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Spoj opće formule (1): gdje (CH2)n-C(=O)Q1 skupina zauzima meta ili para položaj, a R1 i R2 se neovisno jedan o drugome odabiru između H i C1-C4 alkila, n jest 0, 1 ili 2 i Q1 se odabire između: i skupine *-NR8-Q2-A, gdje p jest 1 ili 2, Q2 jest C1-C4 alkilen opcijski supstituiran s OH, R8 jest H ili C1-C4 alkil i A jest piridil opcijski supstituiran s OH, C3-C7 cikloalkil opcijski supstituiran sOH ili pak skupinagdje R3, R4, R5, R6 i R7 jesu istovjetni ili su pak različiti, te se odabiru iz grupe koju tvore H, C1-C4 alkil, OR9, SR9, halogen,CN, CF3, OCF3, COOR9, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenil opcijski supstituiran s 1 do 3 skupine odabrane između OR9, halogena i C1-C4 alkila; gdje R9 i R10 jesu istovjetni ili su pak različiti, te se odabiru između H ili C1-C4 alkila i * predstavlja mjesto vezanja na karbonilnu skupinu; gdje je Q1 skupina supstituirana s barem jednom OH skupinom; ili, gdje je to potrebno, njegove farmaceutski prihvatljive soli i/ili izomeri, tautomeri,solvati ili izotopne varijante. Patent sadrži još32 patentna zahtjeva.Compound of general formula (1): where (CH2)n-C(=O)Q1 group occupies the meta or para position, and R1 and R2 are independently selected from H and C1-C4 alkyl, n is 0, 1 or 2 and Q1 is selected from: and the group *-NR8-Q2-A, where p is 1 or 2, Q2 is C1-C4 alkylene optionally substituted with OH, R8 is H or C1-C4 alkyl and A is pyridyl optionally substituted with OH, C3-C7 cycloalkyl optionally substituted with OH or a group where R3, R4, R5, R6 and R7 are the same or different, and are selected from the group formed by H, C1-C4 alkyl, OR9, SR9, halogen, CN, CF3, OCF3, COOR9, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 and phenyl optionally substituted with 1 to 3 groups selected from OR9, halogen and C1-C4 alkyl; where R9 and R10 are the same or different, and are chosen from H or C1-C4 alkyl and * represents the point of attachment to the carbonyl group; where the Q1 group is substituted with at least one OH group; or, where appropriate, its pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variants. The patent contains another 32 patent claims.

HR20070542T 2004-01-22 2007-11-28 Sulfonamide derivatives for the treatment of diseases HRP20070542T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09
PCT/IB2005/000086 WO2005080313A2 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
HRP20070542T3 true HRP20070542T3 (en) 2008-02-29

Family

ID=34890770

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070542T HRP20070542T3 (en) 2004-01-22 2007-11-28 Sulfonamide derivatives for the treatment of diseases

Country Status (7)

Country Link
CR (1) CR9838A (en)
CY (1) CY1107107T1 (en)
EC (1) ECSP066700A (en)
HK (1) HK1096379A1 (en)
HR (1) HRP20070542T3 (en)
IL (1) IL176564A (en)
MA (1) MA28302A1 (en)

Also Published As

Publication number Publication date
HK1096379A1 (en) 2007-06-01
CY1107107T1 (en) 2012-10-24
IL176564A (en) 2011-11-30
CR9838A (en) 2008-04-21
MA28302A1 (en) 2006-11-01
IL176564A0 (en) 2006-10-31
ECSP066700A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
HRP20070452T3 (en) Sulfonamide derivatives for the treatment of diseases
RS50561B (en) Sulfonamide derivatives for the treatment of diseases
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
ME01421B (en) 5-substituted quinazolinone derivatives as antitumor agents
HRP20090266T1 (en) Malonamide derivatives blocking the activity of gamma-secretase
DK0862567T3 (en) 5-azabicyclo [3.1.0] hexylalkyl-2-piperidones and glutarimides as neurokinin receptor antagonists
AR036032A1 (en) COMPOUND DERIVED FROM QUINOLINA, COMPOSITION THAT INCLUDES IT; USE OF THE SAME IN THE MANUFACTURE OF MEDICINES, PROCESS TO PREPARE IT, AND METHOD TO DETECT AND SELECT AN AGENT THAT MODULATES THE ACTIVITY OF MIF
AR045255A1 (en) DERIVATIVES OF 1,2 BENZODIAZOL
CR10145A (en) USEFUL TROPANAN DERIVATIVES IN THERAPY (DIVISIONAL EXP. 6800)
AR004735A1 (en) CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
AR052887A1 (en) DERIVATIVES OF TIAZOL, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT DISEASES MEDIATED BY THE INHIBITION OF PROTEIN KINASE
RS51280B (en) Novel hydantoin derivatives for the treatment of obstructive airway diseases
AR035617A1 (en) COMPOUNDS DERIVED FROM PHENETHANOLAMINE, COMBINATIONS AND PHARMACEUTICAL FORMULATIONS OF THE SAME, PROCESS FOR THEIR PREPARATION, ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OR PROPHYLAXIS OF A CLINICAL CONDITION FOR WHICH A BETAIEPAR BARDIAR AGENT IS ADDED
AR046297A1 (en) DPP INHIBITORS - IV METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE AGENTS
RS51888B (en) Derivatives of n-(phenyl(piperidin-2-yl)benzamide, the preparation method thereof and application of same in therapeutics
RS51674B (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
RS53180B (en) Novel seh inhibitors and their use
AR057464A1 (en) PROCEDURE FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES
TW200604185A (en) Chemical compounds
AR007108A1 (en) ANTI-TUMOR AND ANTIVIRAL RENTAL AGENTS, PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH AGENTS.
RS51557B (en) 4h-1,2,4-triazin-5-one derivatives, their preparation and their use as alpha 7 nicotinic acetylcholine receptors
HRP20080363T3 (en) Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
SE0201658D0 (en) Immediate release pharmaceutical formulation
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
AR037459A1 (en) ANTAGONISTS VI OF THE CCR-3 RECEIVER